SCHEMBL24980372

SCHEMBL24980372

CN(N)CCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
CA14 Q9ULX7 2/20 0.35
PDK2 Q15119 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA7 P43166 1/20 0.32
FPR3 P25089 1/20 0.32
FPR2 P25090 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1B Q00975 1/20 0.32
CACNA1C Q13936 1/20 0.32
CTSK P43235 2/20 0.31
HTR2C P28335 1/20 0.30
SLC6A4 P31645 1/20 0.30
CTSD P07339 1/20 0.30
CTSL P07711 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10260946 0.89 HDAC6 (0.40) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL19699862 0.83 CHRM2 (0.39) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL3293559 0.82 HDAC6 (0.40) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL19607386 0.82 CA14 (0.39) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL34414 0.82 HDAC6 (0.36) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL20762898 0.82 GBA1 (0.39) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL17337834 0.80 GBA1 (0.36) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL19945257 0.80 GBA1 (0.36) GBA1HDAC6HDAC1HDAC2CA14
SCHEMBL19088681 0.80 GBA1 (0.36) GBA1HDAC6HDAC1HDAC2CA14
Hydrochloric Acid SCHEMBL1026855 0.80 HDAC6 (0.35) GBA1HDAC6HDAC1HDAC2CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF SPARCBIO LLC 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230026856-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF KRAS, NRAS, HRAS GBA1 993/4885HDAC6 1806/4885HDAC1 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.